Tandem Diabetes Care, Inc.

BOVESPA:T2ND34 Stock Report

Market Cap: R$7.8b

Tandem Diabetes Care Management

Management criteria checks 2/4

Tandem Diabetes Care's CEO is John Sheridan, appointed in Apr 2013, has a tenure of 12.08 years. total yearly compensation is $8.53M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth R$11.27M. The average tenure of the management team and the board of directors is 3.9 years and 4.8 years respectively.

Key information

John Sheridan

Chief executive officer

US$8.5m

Total compensation

CEO salary percentage8.59%
CEO tenure12.1yrs
CEO ownership0.1%
Management average tenure3.9yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Sheridan's remuneration changed compared to Tandem Diabetes Care's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$184m

Dec 31 2024US$9mUS$732k

-US$96m

Sep 30 2024n/an/a

-US$127m

Jun 30 2024n/an/a

-US$136m

Mar 31 2024n/an/a

-US$141m

Dec 31 2023US$5mUS$711k

-US$223m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$224m

Mar 31 2023n/an/a

-US$204m

Dec 31 2022US$6mUS$711k

-US$95m

Sep 30 2022n/an/a

-US$68m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

US$6m

Dec 31 2021US$6mUS$690k

US$16m

Sep 30 2021n/an/a

US$22m

Jun 30 2021n/an/a

US$7m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$4mUS$600k

-US$34m

Sep 30 2020n/an/a

-US$49m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$11mUS$500k

-US$25m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$55m

Mar 31 2019n/an/a

-US$113m

Dec 31 2018US$2mUS$386k

-US$123m

Compensation vs Market: John's total compensation ($USD8.53M) is above average for companies of similar size in the BR market ($USD650.21K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Sheridan (69 yo)

12.1yrs
Tenure
US$8,526,238
Compensation

Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 20...

Leadership Team

NamePositionTenureCompensationOwnership
John Sheridan
President12.1yrsUS$8.53m0.14%
R$ 11.3m
Leigh Vosseller
Executive VP7.3yrsUS$2.48m0.069%
R$ 5.3m
Jean-Claude Kyrillos
Executive VP & COOless than a yearUS$2.60m0.016%
R$ 1.3m
Susan Morrison
Executive VP & Chief Administrative Officer11.7yrsUS$2.01m0.056%
R$ 4.4m
Elizabeth Gasser
Executive VP and Chief Strategy & Product Officer3.9yrsUS$2.01m0.034%
R$ 2.7m
Mark Novara
Executive VP & Chief Commercial Officer1.5yrsUS$802.75k0.038%
R$ 2.9m
Rick Carpenter
Chief Technical Officer3.5yrsno data0.032%
R$ 2.5m
Shannon Hansen
Executive VP3.3yrsno data0.028%
R$ 2.2m
Tom Fox
Chief Human Resources Officer7.8yrsno datano data
Jordan Pinsker
Chief Medical Officer1.4yrsno datano data
Christina Sun
VP & Corporate Controller5.2yrsno datano data
3.9yrs
Average Tenure
54.5yo
Average Age

Experienced Management: T2ND34's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Sheridan
President5.9yrsUS$8.53m0.14%
R$ 11.3m
Rebecca Robertson
Independent Chairwoman of the Board6.3yrsUS$343.45k0.014%
R$ 1.1m
Christopher Twomey
Independent Director11.8yrsUS$303.45k0.036%
R$ 2.8m
Peyton Howell
Independent Director4.8yrsUS$298.95k0.025%
R$ 2.0m
Rajwant Sodhi
Independent Director4.3yrsUS$294.60k0.017%
R$ 1.3m
Kathleen McGroddy-Goetz
Independent Director4.9yrsUS$294.93k0.020%
R$ 1.6m
Myoungil Cha
Independent Director2.9yrsUS$288.45k0.011%
R$ 884.5k
Joao Paulo Malagueira
Independent Director2.9yrsUS$289.95k0.011%
R$ 884.5k
4.8yrs
Average Tenure
59yo
Average Age

Experienced Board: T2ND34's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/24 10:32
End of Day Share Price 2025/05/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tandem Diabetes Care, Inc. is covered by 40 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Travis SteedBarclays
Matthew MiksicBarclays